ADALAT Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Adalat, and what generic alternatives are available?

Adalat is a drug marketed by Bayer Pharms and Norwich and is included in two NDAs.

The generic ingredient in ADALAT is nifedipine. There are thirty-nine drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the nifedipine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Adalat

A generic version of ADALAT was approved as nifedipine by ACTAVIS ELIZABETH on January 8^th, 1991.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for ADALAT?
What are the global sales for ADALAT?
What is Average Wholesale Price for ADALAT?

Summary for ADALAT

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	165
Clinical Trials:	29
Patent Applications:	179
Drug Prices:	Drug price information for ADALAT
DailyMed Link:	ADALAT at DailyMed

Drug patent expirations by year for ADALAT

Recent Clinical Trials for ADALAT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cao Yu	Phase 1
Jing Liu	Phase 4
University of Utah	Phase 4

See all ADALAT clinical trials

US Patents and Regulatory Information for ADALAT

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Pharms	ADALAT	nifedipine	CAPSULE;ORAL	019478-001	Nov 27, 1985		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Norwich	ADALAT CC	nifedipine	TABLET, EXTENDED RELEASE;ORAL	020198-002	Apr 21, 1993		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Bayer Pharms	ADALAT	nifedipine	CAPSULE;ORAL	019478-002	Sep 17, 1986		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Norwich	ADALAT CC	nifedipine	TABLET, EXTENDED RELEASE;ORAL	020198-001	Apr 21, 1993		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Norwich	ADALAT CC	nifedipine	TABLET, EXTENDED RELEASE;ORAL	020198-003	Apr 21, 1993		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for ADALAT

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Pharms	ADALAT	nifedipine	CAPSULE;ORAL	019478-002	Sep 17, 1986	⤷ Sign Up	⤷ Sign Up
Bayer Pharms	ADALAT	nifedipine	CAPSULE;ORAL	019478-001	Nov 27, 1985	⤷ Sign Up	⤷ Sign Up
Bayer Pharms	ADALAT	nifedipine	CAPSULE;ORAL	019478-002	Sep 17, 1986	⤷ Sign Up	⤷ Sign Up
Bayer Pharms	ADALAT	nifedipine	CAPSULE;ORAL	019478-001	Nov 27, 1985	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for ADALAT

See the table below for patents covering ADALAT around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Canada	981582	CORONARY DILATOR IN A PHARMACEUTICAL DOSAGE UNIT FORM	⤷ Sign Up
Cyprus	918	CAPSULES COMPRISING A CORONARY-DILATING COMPOUND	⤷ Sign Up
Israel	40165		⤷ Sign Up
Japan	S5434048		⤷ Sign Up
Egypt	10633	PROCESS FOR PREPARATION"A CORONARY AGENT IN SPECIAL FORM AND PROCESSES FOR ITS MANUFACTURE"	⤷ Sign Up
Japan	S58121211	MANUFACTURE OF INSTANTANEOUS MOUTH DISCHARGING SUBLINGUAL SOFT CAPSULE MEDICINE	⤷ Sign Up
Norway	138167		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for ADALAT

Recent Clinical Trials for ADALAT

Make Better Decisions: Try a trial or see plans & pricing